A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2018

At a glance

  • Drugs RA 101495 (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Sponsors Ra Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Design of this trial will be presented at the 4th Congress of the European Academy of Neurology (EAN), according to Ra Pharmaceuticals media release.
    • 05 Jun 2018 According to a Ra Pharmaceuticals media release, 19 patients (over 50% of target enrolment) have been recruited to date.
    • 09 May 2018 According to a Ra Pharmaceuticals media release, fourteen patients have been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top